Skip to main content

Axsome Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 5, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 5, 2024

AXSM$133.96+1.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Item 5. Other Information

During the second quarter of 2024, the following Rule 10b5-1 trading arrangements (as defined in Item 408(a)(1)(i) of Regulation S-K) and non-Rule 10b5-1 trading arrangements (as defined in Item 408(c) of Regulation S-K) intended to satisfy the affirmative defense of Rule 10b5-1(c) of the Exchange Act were adopted or terminated by our directors and/or executive officers:

Adopted

NameTitleDate of Adoption of Rule 10b5-1 Trading Arrangement(1)Scheduled Expiration Date of Rule 10b5-1 Trading ArrangementAggregate Number of Securities to Be Sold
Mark JacobsonChief Operating OfficerMay 10, 2024(2)February 13, 2025Up to 80,575 shares of common stock pursuant to the exercise of non-qualified stock options

(1) Date of adoption of Rule 10b5-1 trading arrangements is in accordance with both the Company’s insider trading policy and applicable SEC rules and regulations.

(2) The first trade pursuant to the Rule 10b5-1 trading arrangement will be, in accordance with both the Company’s insider trading policy and applicable SEC rules and regulations, on a date after the date of adoption of the Rule 10b5-1 trading arrangement.

Terminated

NameTitleDate of Termination of Rule 10b5-1 Trading Arrangement(1)Scheduled Expiration Date of Rule 10b5-1 Trading ArrangementAggregate Number of Securities to Be Sold
Mark JacobsonChief Operating OfficerMay 10, 2024(2)December 29, 2024Up to 86,094 shares of common stock pursuant to the exercise of non-qualified stock options immediately prior to the 10-year expiration dates of such options in 2024(3)

(1) Date of termination of Rule 10b5-1 trading arrangements is in accordance with both the Company’s insider trading policy and applicable SEC rules and regulations.

(2) The date of adoption of this Rule 10b5-1 trading arrangement was August 15, 2023. The first trade pursuant to the Rule 10b5-1 trading arrangement was, in accordance with both the Company’s insider trading policy and applicable SEC rules and regulations, on a date after the date of adoption of the Rule 10b5-1 trading arrangement.

(3) Prior to its termination,38,355 shares of common stock pursuant to the exercise of non-qualified stock options were sold pursuant to this Rule 10b5-1 trading arrangement.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.